{"id":"a4f52f38ad6b","type":"article","url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","title":"2023 ACC Expert Consensus: management van HFpEF","title_en":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.03.393","source_url":"https://doi.org/10.1016/j.jacc.2023.03.393","authors":["Michelle M Kittleson","Gurusher S Panjrath","Kaushik Amancherla","Leslie L Davis","Anita Deswal","Dave L Dixon","James L Januzzi","Clyde W Yancy"],"significance":8,"published":"2023-05-09","source_date":"2023-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"The 2023 ACC Expert Consensus provided a structured decision pathway for HFpEF management, positioning SGLT2 inhibitors as a cornerstone therapy alongside diuretics for volume management, GLP-1 receptor agonists for obesity, and targeted treatment of comorbidities.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ACC expert consensus document geeft een gestructureerd beslispad voor HFpEF-management, inclusief SGLT2-remmers als hoeksteen, diuretica voor decongestie, en inspanningstraining. Het document integreert het DELIVER- en EMPEROR-Preserved-bewijs in de klinische praktijk.","abstract_original":""}